In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Current health news includes a push for board overhaul at Avantor by Engine Capital, Ab&B Bio-Tech's share surge during its ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

We imagine something different, a 100 percent online system that's accessible, personalized, and designed around how people ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.